Additional file 5: Figure S2. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Pinto-Mariz, Fernanda; Rodrigues Carvalho, Luciana; Prufer De Queiroz Campos Araujo, Alexandra; De Mello, Wallace; GonĂ§alves Ribeiro, MĂĄrcia; Cunha, Maria; Cabello, Pedro; Riederer, Ingo; Negroni, Elisa; Desguerre, Isabelle; Veras, Mariana; Yada, Erica; Allenbach, Yves; Benveniste, Olivier; Voit, Thomas; Mouly, Vincent; Silva-Barbosa, Suse; Butler-Browne, Gillian; Savino, Wilson

doi:10.6084/m9.figshare.c.3615224_D2.v1

13395_2015_66_MOESM5_ESM.doc (69 kB)

Additional file 5: Figure S2. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

journal contribution

posted on 2015-12-10, 05:00 authored by Fernanda Pinto-Mariz, Luciana Rodrigues Carvalho, Alexandra Prufer De Queiroz Campos Araujo, Wallace De Mello, MĂĄrcia GonĂ§alves Ribeiro, Maria Cunha, Pedro Cabello, Ingo Riederer, Elisa Negroni, Isabelle Desguerre, Mariana Veras, Erica Yada, Yves Allenbach, Olivier Benveniste, Thomas Voit, Vincent Mouly, Suse Silva-Barbosa, Gillian Butler-Browne, Wilson Savino

Lack of differences between DMD patients and healthy control in relative numbers of CD14/CD49dhi and CD19/CD49dhi cells. (DOC 69 kb)

Funding

PPMD

History

Usage metrics

Keywords

Duchenne muscular dystrophy Inflammation CD49d T lymphocytes Predictive biomarker Immunotherapy

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 5: Figure S2. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Funding

PPMD

History

Usage metrics

Categories

Keywords

Licence

Exports